Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

Update on Treatment of Clostridioides difficile Infection

2020; Elsevier BV; Volume: 95; Issue: 4 Linguagem: Inglês

10.1016/j.mayocp.2019.08.006

ISSN

1942-5546

Autores

Janice Cho, Darrell S. Pardi, Sahil Khanna,

Tópico(s)

Nosocomial Infections in ICU

Resumo

Clostridioides difficile infection (CDI) is the leading cause of health care-associated infections in the United States. The increasing incidence and recurrence rates of CDI together with its associated morbidity and mortality are great concerns. Newer treatment methods, such as narrow-spectrum antibiotics, monoclonal antibodies, and microbial replacement therapies, are being developed and implemented. We searched PubMed to identify published literature from 2010 to 2018 using the following keywords: Clostridium difficile, treatment, and therapy. Cited references were also used to identify relevant literature. This review focuses on the current standard of therapy and emerging therapies for CDI and summarizes the updated guidelines on treatment of CDI.

Referência(s)